This trial is evaluating whether Treatment will improve 7 primary outcomes in patients with Genetic Disease. Measurement will happen over the course of Up to 4 years.
This trial requires 400 total participants across 0 different treatment group
"In the United States, 11.4 million children are afflicted with a common group of diseases that, at ages under 5, typically result in death, serious illness, or long-lasting disabling conditions. If the pattern of infant, neonatal, and infant mortality is replicated in the United States, an estimated 2.6 million children of age 5 years are likely to suffer from at least one major disabling condition. Infant mortality, neonatal encephalopathy, and perinatal asphyxia are leading causes of death of children up to age 5 years in the United States." - Anonymous Online Contributor
"In an infant, the first signs include the presence of a cold or flu-like disorder, irritability, vomiting, or diarrhea. The white blood cell and platelet count are also signs of infant, newborn, diseases." - Anonymous Online Contributor
"Prenatal exposures may increase the risk of developing neonatal diseases. These exposures are linked to both genetic and physiological factors and may be modifiable risk factors." - Anonymous Online Contributor
"Many disorders, including some that are still in childhood and are not curable, can be prevented in childhood and later in adulthood by improved early detection and appropriate intervention." - Anonymous Online Contributor
"Treatment for infants, newborns and diseases depends on the symptoms of the patient, the amount of treatment needed, and the type of treatment available. Common options include surgery, chemotherapy, and radiation. Common diseases include pneumonia, gastroesophageal reflux, and respiratory tract infections, along with other common illnesses." - Anonymous Online Contributor
"Infant, newborn, diseases are conditions that arise mostly in children under 18 months of age. The underlying pathophysiology is usually a combination of genetic susceptibility and environmental factors. Infant, newborn, diseases are considered as a separate category because their management is different from diseases of other age groups.\n" - Anonymous Online Contributor
"A systematic review of placebo controlled trials indicates that many treatments are more effective than a placebo. Treatment studies should use placebo controls as the standard of comparison with which to assess the benefits of treatment. To avoid the confounding effects of a non-blinded placebo, blinding should always be used to eliminate any effect that treatment may have on the outcome of the treatment or the placebo group." - Anonymous Online Contributor
"Infant, newborn, disease are more serious with respect to potential severity than diseases (especially in infancy and early childhood), which may cause concerns and/or worries for caregivers. As an example, the effects of a mild influenza illness are usually limited and resolve within a few days, whereas more serious illnesses like pneumonia can be devastating or even fatal." - Anonymous Online Contributor
"There is currently some clinical evidence available for the efficacy of dermatological treatments used to treat [acne scar](https://www.withpower.com/clinical-trials/acne-scar)s. However, the studies evaluated only clinical measures, such as acne scores and acne scales, or involved an observational design, and no meta-analysis has been published. For now, practitioners cannot recommend any treatments over others." - Anonymous Online Contributor
"Clinical trial data should be used cautiously and be considered a starting point for decision making, but there is no evidence to support that any one tinnitus treatment is more successful than another." - Anonymous Online Contributor
"In most cases, treatment aims to improve symptoms or reduce pain. There is increasing evidence that disease-modifying therapies are equally effective as symptomatic therapies for improving quality of life in [rheumatoid arthritis](https://www.withpower.com/clinical-trials/rheumatoid-arthritis) and other forms of inflammatory arthritis. Studies have shown that disease-modifying therapies prevent progression to more severe arthritis. Many of these therapies reduce systemic or localized inflammation, relieve joint pain, improve function, or reduce systemic symptoms. However, most of the medications used to treat arthritis are effective in only part of the patients. Patients with multiple types of arthritis may require a variety of treatments to get the best effect. One possible option is that they may also receive treatments that prevent or slow down the progression of arthritis by reducing inflammation." - Anonymous Online Contributor
"It can be concluded that infant, newborn, and primary diseases were of different origins. Therefore, it could not be determined that any one of these diseases is the cause of the other." - Anonymous Online Contributor